摘要
Colorectal cancer(CRC)is the second most common cancer and the most common type of gastrointestinal cancer with rapidly increasing incidence and mortality in China(1,2).Since the first edition of the Chinese Society of Clinical Oncology(CSCO)guideline was published in2017,the guideline has been updated annually according to the latest results of clinical research at home and abroad,the accessibility of drugs and the opinions of CSCO experts(3-7).
基金
supported by the Provincial Key R&D Program of Zhejiang Province(No.2021C03125)
Beijing Xisike Clinical Oncology Research Foundation(No.Y-tongshu2021/ms-0003)。
